
Piramal Pharma Limited has informed the Exchange regarding a press release dated October 23, 2024, titled "Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2024".
Filed with NSE · · 30 pages · English
The company reported a year-on-year revenue increase driven by strong performance in its Contract Development and Manufacturing Organization (CDMO) segment. Additionally, Piramal Pharma is planning a substantial expansion at its Lexington facility to enhance its sterile fill-finish capabilities. The results reflect the company's commitment to sustainability and its long-term financial goals.
Written by 6ix AI from the company’s filing. How 6ix writes summaries

Piramal Pharma Limited has informed the Exchange regarding a press release dated October 23, 2024, titled "Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and half year ended 30th September, 2024".
Follow Piramal Pharma into a list and get an email when it puts out news.
Follow Piramal Pharma